Corosan (Dipyridamole)

Quick links

Choose a section

Quick links to important sections

Advertisements

Corosan (Dipyridamole)

Advertisements
Advertisements

Overview of Corosan (Dipyridamole)

Quick Facts

Property Description
Active ingredient Dipyridamole
Form Oral Tablet, Intravenous Solution
Pharmacological class Antiplatelet Agent, Vasodilator Agent
General purpose To prevent blood clot formation and improve blood flow
Origin Synthetic Compound (Pyrimidopyrimidine derivative)

Corosan is a medication whose active component is the synthetic chemical substance Dipyridamole, which is classified primarily as an Antiplatelet Agent and Vasodilator Agent. The drug is designed to alter blood properties and vessel behavior to promote smoother circulation, a function that is clinically recognized for its significance in vascular health management.

Defining the Active Ingredient and Pharmacological Class

The active ingredient of Corosan is Dipyridamole (INN), a unique synthetic organic compound developed as a derivative of the pyrimidopyrimidine structure. This dual action agent is categorized as both a Vasodilator Agent—promoting the widening of blood vessels—and an Antiplatelet Agent, as it inhibits the aggregation, or sticking together, of blood platelets. Dipyridamole’s mechanism is supported by pharmacological studies confirming its distinct capability to modify platelet function and vessel tone, setting it apart from agents with single modes of action.

Composition and Available Pharmaceutical Forms

Dipyridamole is typically used as a single-active-ingredient product; however, its effectiveness often leads to its use as an adjunct, or in fixed-dose combinations, alongside other antiplatelet drugs. The medication is presented in two principal forms: the Oral Tablet and an Intravenous Solution. Notably, the oral preparations include both immediate-release and extended-release formats, allowing tailored patient management. The solution is reserved for administration via the Intravenous Route of administration and is a key component in specialized diagnostic procedures, such as pharmacological cardiac stress testing.

General Function and Purpose

The overall function of Dipyridamole is to improve the flow of blood through the circulatory system by concurrently reducing the blood’s natural tendency to form internal clots and enhancing vessel dilation. The fundamental purpose of this medication, which has been established in clinical practice since the 1960s, is to help maintain an unrestricted pathway for blood to travel, offering a proactive means of managing vascular complications in high-risk patient groups.

Advertisements

What side effects are possible with Corosan (Dipyridamole)?

Possible Side Effects and Safety Information

The safety profile of Dipyridamole, as documented in official regulatory labeling, is classified according to the frequency and type of effects observed. These classifications indicate the potential risk profile, strictly excluding any therapeutic claims or usage instructions.

Frequency-Classified Adverse Reactions

Adverse effects are categorized by System-Organ Class (SOC) based on official regulatory standards:

Classification Common Side Effects (Examples) Affected Systems
Very Common Headache, Dizziness, Diarrhea, Nausea Nervous System, Gastrointestinal
Common Vomiting, Flushing, Hypotension, Angina Pectoris, Rash Vascular, Cardiac, Skin

Headache and dizziness are frequently observed at the start of therapy and may be classified as transient with continued use, according to regulatory documents.

Serious Adverse Reactions and Safety Constraints

Regulatory documents list certain reactions classified as serious or requiring specific consideration. Due to its antiplatelet activity, the drug carries a potential for Serious Bleeding Events (Hemorrhage), including cerebral hemorrhage. Exacerbation of underlying Coronary Artery Disease symptoms, such as angina pectoris, is also a documented concern, particularly in patients with pre-existing severe CAD.

Safety constraints necessitate caution in certain populations, including those with severe hepatic insufficiency or pre-existing hypotension. The drug is generally contraindicated in patients with a known hypersensitivity to the active substance.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

A suspected or realized overdose of Dipyridamole necessitates immediate emergency medical attention. Official regulatory guidance mandates that individuals contact a Poison Control Center or seek medical assistance immediately for any suspected overexposure. Careful medical management is considered an essential component of the response.

Documented Clinical Manifestations

Regulatory documentation indicates that overdose exposure may present with several non-specific clinical signs. These commonly include symptoms such as a warm feeling, flushes, sweating, restlessness, feelings of weakness, and dizziness. The most serious officially documented outcomes involve the cardiovascular system, potentially resulting in a significant drop in blood pressure (hypotension) and an elevated heart rate, known as tachycardia.

Emergency Management Procedures

The officially documented management strategy emphasizes symptomatic and supportive treatment. Specific procedures to be considered include gastric lavage and the potential administration of a vasopressor drug. Additionally, the administration of xanthine derivatives, such as aminophylline, is noted in regulatory documents as a measure that may reverse the cardiovascular hemodynamic effects of the overdose. It is officially stated that dialysis is not likely to be of benefit, which is attributed to the high degree of protein binding of the active substance.

Advertisements

Therapeutic Uses of Corosan (Dipyridamole)

What Corosan (Dipyridamole) Treats: Main Uses and Benefits

Corosan (Dipyridamole) is applied in managing the symptomatic risk associated with blood clot formation in high-risk situations. This medication is commonly used across conditions presenting with episodic or fluctuating manifestations, specifically following a transient ischemic attack (TIA) or minor stroke, and for patients with mechanical prosthetic heart valves. Dipyridamole is used to address symptomatic risk associated with blood clots, which may assist in managing the risk of further episodes.

It is applied in addressing symptomatic risk by supporting the patient in managing the risk of serious vascular events that create noticeable physiological strain. It is relevant for managing symptom clusters that may become intense or disruptive.

“This medication is considered relevant for easing the impact of symptoms linked to organ-specific functional stress.”

This support helps maintain a sense of stability when symptoms are more noticeable, assisting with maintaining functional stability and contributing to improved comfort during symptomatic periods.


Quick Fact: Support for Symptoms that Interfere with Daily Functioning

Advertisements

Eligibility and Restrictions for Use

The official regulatory labeling for Dipyridamole strictly defines which populations are eligible to use the medication.

Use is absolutely contraindicated for patients who have a known hypersensitivity to Dipyridamole or to any of the product's excipients. Additionally, some oral formulations are prohibited for individuals with rare hereditary conditions such as fructose intolerance or glucose-galactose malabsorption.

Use requires caution and close monitoring for patients presenting with certain underlying conditions. This includes individuals with severe coronary artery disease, haemodynamic instability, coagulation disorders, or significant hepatic insufficiency.

Age-related restrictions apply primarily to younger groups. The medication is not recommended for the pediatric population below 12 years of age because safety and effectiveness have not been established by regulators. Conversely, use in older adults is generally permitted without requiring a standard dosage adjustment.

Regarding reproductive status, the label restricts use during pregnancy to only if clearly needed. Use during breastfeeding is also conditional, permitted only if considered essential by a physician, as the active substance is known to be excreted in human milk.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Dipyridamole outlines interactions primarily based on pharmacodynamic and transporter effects, rather than metabolic pathways.

Pharmacodynamic Interactions and Contraindications

Co-administration with other Antiplatelet or Anticoagulant Agents, such as Warfarin or Aspirin, increases the risk of bleeding due to additive effects on blood properties. The combination with specific agents like Riociguat is formally contraindicated due to the risk of additive systemic hypotension, aligning with Dipyridamole's vasodilatory action. The hypotensive effects of blood pressure-lowering medicines may also be enhanced.

Transporter-Mediated and Exposure Changes

Regulatory documentation indicates Dipyridamole can inhibit drug transporters, including P-glycoprotein (P-gp) and BCRP. This inhibition leads to increased plasma exposure and potential effects of co-administered substances, such as Betrixaban or Acalabrutinib. Additionally, Dipyridamole increases the plasma levels and cardiovascular effects of Adenosinergic agents.

Administration Timing and Non-Medicinal Interactions

Specific timing rules are mandated for certain procedures: oral Dipyridamole must be interrupted for 48 hours prior to pharmacological cardiac stress testing involving intravenous Dipyridamole. Interactions with non-medicinal products are also documented: Alcohol may increase the rate of absorption of the prolonged-release capsule, and agents that raise gastric pH, like Antacids, may reduce the absorption of the immediate-release tablet.

Advertisements

Mechanism of Action

How Corosan (Dipyridamole) Works

Dipyridamole acts upon specific molecular and cellular pathways within the circulatory system through a dual mechanism focusing on adenosine and cyclic nucleotide signaling.

Potentiation of Endogenous Adenosine Signaling

Dipyridamole acts by increasing the concentration and duration of the endogenous signaling molecule, adenosine, in the extracellular space. This is achieved through the non-competitive inhibition of the Equilibrative Nucleoside Transporter (ENT1) and the enzyme Adenosine Deaminase (ADA). By preventing the rapid reuptake and breakdown of adenosine, the drug amplifies the subsequent activation of A2 receptors on the vascular smooth muscle cells, directly promoting arteriolar vasodilation and leading to changes in local flow distribution.

Intracellular Cyclic Nucleotide Elevation

A second, complementary mechanism involves the inhibition of Phosphodiesterase (PDE) enzymes, particularly PDE Type 3 and PDE Type 5, which are responsible for degrading intracellular cAMP and cGMP. In platelets, the resulting increase in cAMP levels suppresses the internal release of calcium and subsequent signal transduction necessary for platelet activation. This sequence inhibits platelet adhesion and aggregation, resulting in an antiplatelet effect characterized by suppressed platelet activation.

️ Mechanism Constraints

The physiological effects are inherently constrained by the drug's fundamental mechanism. The vasodilation is non-selective, which can lead to a redistribution of blood flow known as "coronary steal" in situations where severely stenotic coronary arteries exist. Additionally, the actions relying on adenosine potentiation are susceptible to competitive inhibition by external xanthine molecules (e.g., caffeine), which competitively inhibits the signaling at the A2 receptors.

Advertisements

Dosage and Administration Information

Administration and Dosage

Corosan, containing the active ingredient Dipyridamole, is prescribed primarily to reduce the risk of blood clots (thromboembolism), particularly following heart valve replacement. It is also used as part of a combination regimen for secondary prevention of ischemic stroke.

Oral Dosage Form (Tablets/Capsules)

  • Tablet/Liquid: The typical adult oral dose for thromboembolism prophylaxis, when used as an adjunct to an anticoagulant like warfarin, is 75 mg to 100 mg four times a day (every 6 hours).
  • Extended-Release Capsules: For secondary stroke prevention, the combination of extended-release dipyridamole (200 mg) and aspirin (25 mg) is typically taken as one capsule twice daily (morning and evening). The capsules should be swallowed whole and should not be chewed.

General Instructions:

  1. Take Dipyridamole exactly as directed by your prescribing physician. Do not take more or less than the prescribed amount.
  2. Try to take doses at regularly spaced intervals to maintain a constant level of the medication in your blood.
  3. For standard tablets, taking the medication at least one hour before or two hours after meals may improve effectiveness.
  4. Continue taking this medication even if you feel well. Do not stop without consulting your doctor, as this may increase your risk of a serious thromboembolic event.

Missed Dose:

If you miss a dose, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not take a double dose to compensate for a missed one.

Advertisements

Recent Clinical Evidence

Corosan (Dipyridamole): Recent Clinical Evidence

Evidence for Therapeutic Uses

Research has extensively examined the use of Dipyridamole (Corosan) in two main therapeutic contexts. For preventing recurrent stroke or TIA, the evidence is primarily drawn from large-scale Randomized Controlled Trials (RCTs) and meta-analyses. These studies focused on adult patients and examined the occurrence of recurrent vascular events. Findings related to the immediate-release formulation were often mixed, while later research on an extended-release formulation studied alongside aspirin reported event frequency measurements that were lower in the combination group.

Dipyridamole was also evaluated as an added therapy for patients with mechanical heart valve replacement. The studies monitored individuals already receiving oral anticoagulant therapy and reported event frequency measurements that were lower when the drug was included in the regimen. Crucially, the evidence focuses on the drug being studied in addition to oral anticoagulation, with limited information about using Dipyridamole alone for either primary therapeutic use.

Evidence for Diagnostic Procedures and Research Gaps

Dipyridamole was studied for use in a specific diagnostic procedure for coronary artery disease, where it acts as a coronary vasodilator agent. Studies examined the diagnostic efficacy of the procedure, specifically measuring the sensitivity and specificity of the imaging test in identifying areas of impaired blood flow.

Regarding follow-up, key clinical research featured extended, long-term follow-up durations of two years or more, allowing researchers to monitor the consistency of observed patterns. However, long-term effects are not fully established beyond the primary trial windows. Data for certain groups remain insufficient, with limited information available specifically describing how findings apply to older adults or those with complex comorbidities, meaning that research is ongoing to fully explore these areas.

Key Studies & References

  1. NICE Guideline NG128: Transient loss of consciousness ('blackouts') management (Reference for TIA/stroke prevention guideline use)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Corosan (Dipyridamole) (FAQ)

Q: Why do I get a headache when I start taking Corosan?

A: The official product information indicates that headache is a very common side effect, particularly when starting treatment. This is understood to be related to Dipyridamole's action as a vasodilator, meaning it widens blood vessels. Headaches are often classified as transient, suggesting they may lessen or resolve with continued use.

Q: Why does Corosan sometimes cause flushing or a feeling of warmth?

A: Flushing, or a feeling of warmth, is listed as a common side effect in official regulatory documents. This effect is attributed to the drug's mechanism as a vasodilator, which increases blood flow in the body.

Q: Is Corosan the same as the IV form of the medicine used for heart stress tests?

A: Corosan, containing Dipyridamole, is available in both oral (tablet/capsule) and intravenous (injection) forms. The oral form is used therapeutically to help prevent blood clots. The intravenous form, however, is reserved for use as part of a specialized diagnostic procedure, such as a pharmacological heart stress test.

Q: Is Corosan classified as a standard 'blood thinner'?

A: Official information classifies Dipyridamole as an antiplatelet agent, which is a distinct pharmacological class. This means its primary function is to prevent blood platelets from sticking together. It is not classified as an anticoagulant, which are the agents most commonly referred to as 'blood thinners.'

Q: What is the difference between an antiplatelet drug like Corosan and an anticoagulant?

A: Antiplatelet agents, like Dipyridamole, work by preventing blood platelets from clumping together to form an initial clot. Anticoagulants, in contrast, inhibit specific chemical pathways within the blood to delay the entire clotting process. Both are distinct methods used to manage blood clot risk.

Q: What signs of liver problems should be monitored while on Corosan?

A: The official product label describes signs of potential liver issues that have been documented in regulatory information. These include upper stomach pain, itching, loss of appetite, dark urine, and jaundice (yellowing of the skin or eyes).

Q: Does Corosan have a noticeable effect on my energy levels or general feeling of tiredness?

A: According to official regulatory documentation, unusual tiredness or weakness is listed as a rare side effect of the medication.

Q: Can I take Corosan with over-the-counter pain relievers?

A: Official sources state that it is generally safe to take paracetamol (acetaminophen) with Dipyridamole. However, combining it with other pain relievers, particularly NSAIDs like ibuprofen or high-dose aspirin, may increase the potential risk of bleeding and is typically only done under professional guidance.

Q: Are there any vitamins or supplements that are known to interact with Corosan?

A: Official documents suggest caution with any vitamins, herbal remedies, or supplements that may affect blood properties, such as ginkgo. Official documents advise that patients discuss all supplements being taken with their healthcare provider, as regulatory bodies generally do not test these products for drug interactions.

Q: Should I avoid specific foods that might affect how Corosan works?

A: Official warnings related to food are primarily aimed at individuals undergoing a diagnostic procedure involving the intravenous form. Caffeine-containing products are typically avoided for at least 24 hours prior to this specific diagnostic procedure, as caffeine may interfere with the drug's action in dilating the arteries. No specific dietary restrictions are generally mandated for the oral therapeutic form.

Q: Can taking Corosan affect the reliability of contraception?

A: Official regulatory content indicates that Dipyridamole does not typically reduce the effectiveness of oral contraceptives. However, if the medication causes severe vomiting or diarrhea lasting more than 24 hours, the absorption and reliability of oral contraceptive pills may be reduced.

Q: Will Corosan affect my ability to drive or operate machinery?

A: Official labeling indicates that this medication can cause side effects such as dizziness, headache, or lightheadedness. If these common side effects occur, engaging in activities that require full attention, such as driving or operating machinery, may be unsafe.

Q: What should I know about taking Corosan if I have a history of stomach ulcers?

A: Official regulatory documents caution that patients with a history of a stomach ulcer or bleeding should be monitored due to the increased risk of bleeding. This risk is particularly noted if Dipyridamole is used in combination with aspirin.

Q: Does Corosan have any known effect on a condition called myasthenia gravis?

A: Official documentation indicates that Dipyridamole is associated with precaution in patients with myasthenia gravis. This is especially relevant for those also receiving therapy with cholinesterase inhibitors, as they may experience a worsening of their disease.

Q: What is the brand name equivalent of Corosan (Dipyridamole)?

A: The common brand name for the Dipyridamole tablet formulation is Persantine, according to official regulatory sources. The combination extended-release capsule with aspirin is sold under other distinct brand names.

Q: If I need to have dental work or surgery, do I need to temporarily stop Corosan?

A: Official guidance indicates that for procedures with a low risk of bleeding, Dipyridamole is generally continued. However, for procedures associated with a high risk of bleeding, temporary interruption of treatment may be considered the day before. The decision regarding interruption of treatment must be made by a healthcare provider based on the individual patient and procedure.

Q: How long has Corosan (Dipyridamole) been used in medicine?

A: Official regulatory sources and historical data confirm that the active ingredient Dipyridamole has been established in clinical practice since the 1960s.

Q: Does Corosan increase the general risk of bleeding or bruising?

A: The product label includes explicit warnings regarding the potential for serious bleeding events (hemorrhage) due to the antiplatelet activity of the drug. Official studies have reported that when Dipyridamole is used with warfarin, the observed bleeding risk was not greater than the risk associated with warfarin used alone.

Q: Is it true that taking Corosan can sometimes cause chest pain?

A: Official regulatory documents list chest pain, or angina pectoris, as a common side effect of Dipyridamole. Official information also notes that symptoms of underlying severe coronary artery disease may be aggravated in certain patients.

Q: Why is Corosan not recommended with adenosine?

A: Official drug interaction sections report that Dipyridamole increases the plasma levels and cardiovascular effects of adenosine and similar agents. This interaction may require an adjustment in the adenosine dosage or could increase the risk of related side effects.

Q: Do indigestion remedies need to be separated from the time I take Corosan?

A: Official regulatory documents advise that agents that raise gastric pH, such as antacids, may reduce the absorption of the immediate-release tablet formulation. To avoid reduced absorption of the immediate-release tablet formulation, official regulatory documents state that these remedies must not be taken at the same time.

Q: Is Corosan a suitable medication for children or teenagers?

A: According to official regulatory information, the oral form of this medication is generally not approved for use by anyone younger than 12 years old. This restriction exists because safety and effectiveness in the pediatric population have not been established by regulators.

Q: Is it safe to continue Corosan during pregnancy or while breastfeeding?

A: Official regulatory documents restrict use during pregnancy to only if clearly needed. Use during breastfeeding is also conditional, permitted only if considered essential by a physician, as the active substance is known to be excreted in human milk.

Advertisements

How should Corosan (Dipyridamole) be stored and disposed of?

How to Store and Dispose of Dipyridamole (Corosan)

Official regulatory documentation outlines specific requirements to maintain the stability and quality of Dipyridamole.

Storage Requirements

Formulation Temperature and Protection Container and Handling
Oral Tablets Store at Controlled Room Temperature (CRT), 20°C to 25°C. Protect from moisture. Must be stored in the original container and kept tightly closed.
Injection Store at room temperature. Must be protected from light and should not be frozen. Keep out of the sight and reach of children.

Some prolonged-release capsules must not be stored above 25°C, and any remaining product in the bottle must be discarded six weeks after first opening.

Disposal

All unused or expired Dipyridamole product must be disposed of in accordance with local requirements. The medication must not be thrown into household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Corosan (Dipyridamole) found in:

A-Z Index: